Weathers, Shiao-Pei
Han, Xiaosi
Liu, Diane D.
Conrad, Charles A.
Gilbert, Mark R.
Loghin, Monica E.
O’Brien, Barbara J.
Penas-Prado, Marta
Puduvalli, Vinay K.
Tremont-Lukats, Ivo
Colen, Rivka R.
Yung, W. K. Alfred
de Groot, John F.
Funding for this research was provided by:
National Institutes of Health (1R21CA152024-01, CCSG-P30 CA016672)
Article History
Received: 9 February 2016
Accepted: 3 July 2016
First Online: 12 July 2016
Compliance with ethical standards
:
: S. W. serves on the advisory board for Actelion. X. H. has no disclosures. D. L. has no disclosures. C. C. has consultant relationships with Actelion, DNAtrix, Reata Pharma, Newlink Genetics and Cytrx Corp. M. G. has no disclosures. M. L. has no disclosures. B. O. has no disclosures. M. P-P. has no disclosures. V. P. is a consultant for Orbus Therapeutics, Foundation Medicine, Celgene, Genetech, and Merck. I. T-L. has no disclosures. R. C. has no disclosures. W. Y. is a consultant and serves on the advisory board for Actelion, DNATrix, Merck, and Novartis. J. D. serves on the advisory board for Genentech, Inc., Novartis, Celldex Therapeutics, and Foundation Medicine, Inc. J. D. serves on the DSMB for VBL Therapeutics and is a consultant for Celldex Therapeutics, OXiGENE, Omniox, Inc. and Deciphera Pharmaceuticals. J. D. receives research support from Sanofi-Aventis, AstraZeneca, EMD-Serono, Eli Lilly, Novartis, and Deciphera Pharmaceuticals.